GlassScriptPhysician profile
Hannah Schklar
NPI 1437700523
$1,723.47
in general payments reported to CMS, 2019-2025
14 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $225 · 2023: $514 · 2024: $455 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $332.30 | 2021-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $287.69 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.20 | 2022-2024 | Jardiance |
| Abiomed | $180.31 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $141.68 | 2024 | Opsumit, Uptravi |
| Daxor Corporation | $123.56 | 2023 | Bva-100 |
| E.R. Squibb & Sons, L.L.C. | $120.28 | 2022-2024 | Camzyos |
| Medtronic, INC. | $117.01 | 2023 | Reveal Linq |
| Pfizer INC. | $47.06 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $46.86 | 2024 | |
| Merck Sharp & Dohme LLC | $45.77 | 2023 | Verquvo |
| Vifor Pharma, INC. | $34.61 | 2021-2023 | Veltassa |
| Kiniksa Pharmaceuticals, LTD. | $17.41 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $15.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Schklar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.